At the annual meetings of the American Endocrine Society (ENDO) of 2007 and 2008, Prof. Denis Richard of the Centre de recherche de l'Institut de cardiologie et de pneumologie de Quebec, in collaboration with AEterna Zentaris, presented posters showing that the ghrelin receptor antagonist AEZS-123 reduced body weight gain and fat accumulation in an animal model of diet-induced obesity.
About the Food and Alcohol Addiction Market
There is no safe and effective appetite suppressant currently on the market. It is estimated that between 34 million and 61 million Americans are obese, and the worldwide incidence of obesity is increasing by an estimated 1% per year.
Alcohol dependence is a complex and chronic disease which leads to adverse consequences affecting not only the patients but also their immediate family and has a profound economic burden on society. The annual costs to the United States are estimated to be US$185 billion for alcohol addiction. In 2005, the number of people affected by alcohol problems in the United States was estimated at 15.4 million.
About AEterna Zentaris Inc.
AEterna Zentaris Inc. is a global biopharmaceutical company focused on endocrine therapy and oncology, with proven expertise in drug discovery, development and commercialization. News releases and additional information are available at www.aezsinc.com.
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include,
|SOURCE AETERNA ZENTARIS INC.|
Copyright©2009 PR Newswire.
All rights reserved